Bromocriptine in the Treatment of Peripartum Cardiomyopathy

Inclusion Criteria: 1. Age ≥ 18 years; 2. Peripartum cardiomyopathy defined by the following criteria: * Development of heart failure in the last month of pregnancy or within 5 months of delivery; * Absence of an identifiable alternative cause of heart failure; * Absence of recognizable heart disease prior to the last month of pregnancy; * Left ventricular systolic dysfunction demonstrated by classic echocardiographic criteria, such as depressed ejection fraction; 3. Recent onset of PPCM ( 1 month); 4. Written informed consent. Exclusion Criteria: 1. Hypersensitivity or contraindication to bromocriptine; 2. Patients already taking bromocriptine for PPCM or for another indication; 3. Cardiogenic shock before enrolment; 4. Survival expected to be less than 1 year due to non-cardiovascular causes (eg. cancer); 5. Participation to another investigational drug or investigational device study within 30 days prior to randomization (participation to registries is allowed); 6. Patients who in the opinion of the investigator will not comply with specified drugs, or follow-up evaluation.